

TRADEMARK ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	ASSIGNS THE ENTIRE INTEREST AND THE GOODWILL		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
FEI Women's Health, LLC		10/14/2005	LIMITED LIABILITY COMPANY: DELAWARE
RECEIVING PARTY DATA			
Name:	Duramed Pharmaceuticals, Inc.		
Street Address:	5040 Duramed Drive		
City:	Cincinnati		
State/Country:	OHIO		
Postal Code:	45213-2520		
Entity Type:	CORPORATION: DELAWARE		
PROPERTY NUMBERS Total: 1			
Property Type	Number	Word Mark	
Serial Number:	78676157	BIRTH CONTROL THAT FITS YOUR LIFE	
CORRESPONDENCE DATA			
Fax Number:	(202)371-2540		
	<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>		
Phone:	(202) 371-2600		
Email:	tdurkin@skgf.com		
Correspondent Name:	Tracy-Gene G. Durkin		
Address Line 1:	1100 New York Avenue, NW		
Address Line 4:	Washington, DISTRICT OF COLUMBIA 20005		
ATTORNEY DOCKET NUMBER:	1710.8160000/TGD/JDS		
NAME OF SUBMITTER:	Tracy-Gene G. Durkin		
Signature:	/Tracy Durkin/		
Date:	02/05/2007		

OP \$40.00 78676157

Total Attachments: 6

source=1710BIRTHCONTROL#page1.tif

source=1710BIRTHCONTROL#page2.tif

source=1710BIRTHCONTROL#page3.tif

source=1710BIRTHCONTROL#page4.tif

source=1710BIRTHCONTROL#page5.tif

source=1710BIRTHCONTROL#page6.tif

PURCHASE AGREEMENT

by and among

COPPER 380T LLC;

FEI WOMEN'S HEALTH, LLC;

**The Individuals
Listed on
the Signature Pages Hereto;**

and

Duramed Pharmaceuticals, Inc.

Dated as of October 14, 2005

PURCHASE AGREEMENT, dated as of October 14, 2005 (this "Agreement"), by and among COPPER 380T LLC, a Delaware limited liability company (the "Company"), FEI Women's Health, LLC, a Delaware limited liability company ("FWH"), Tincum Capital Partners, L.P. ("Tincum"), Tincum Capital Partners Parallel Fund, L.P., Tincum Capital Partners Executive Fund I, L.L.C., Craig Capital Corporation ("Craig Capital"), the Persons (as defined in Section 2.3 hereof) listed on the signature pages hereto (each of the parties designated as Sellers in the signature pages hereto a "Seller" and collectively the "Sellers") and Duramed Pharmaceuticals, Inc., a Delaware corporation ("Buyer") and Subsidiary of Barr Pharmaceuticals, Inc. ("Barr").

WITNESSETH

WHEREAS, prior to the Closing (as defined in Section 1.2 hereof), the Company will effect a restructuring (the "Restructuring") that will result in FWH becoming a Subsidiary (as defined in Section 2.3 hereof) of the Company; the Restructuring will be accomplished pursuant to the Agreement and Plan of Reorganization (the "Restructuring Agreement") substantially in the form attached hereto as Exhibit A; unless otherwise indicated herein or the context otherwise requires, references in this Agreement to the Company's Subsidiaries are intended to include FWH as if the Restructuring were effective as of the date hereof;

WHEREAS, as a result of the Restructuring, all of the Units (as defined in Section 2.2 hereof) and UARs (as defined in Section 1.1(a) hereof) of FWH will convert into Units and UARs of the Company, all EARs (as defined in Section 1.1 (b) hereof) of FWH will be cancelled and all EARs of the Company will be adjusted, all as set forth in the Restructuring Agreement;

WHEREAS, the Sellers own or hold all of the outstanding Units (as defined in Section 1.1(c) hereof) of the Company;

WHEREAS, all UARs (as defined in Section 1.1(a) hereof) and EARs (as defined in Section 1.1(b) hereof) and any other Equity Securities of the Company (other than the Units) shall be settled by the Company immediately prior to the Closing; and

WHEREAS, Buyer desires to acquire all of the outstanding Units from the Sellers, and the Sellers who hold any Units desire to sell such Units to the Buyer upon the terms and subject to the conditions set forth herein.

NOW, THEREFORE, in consideration of the representations, warranties, covenants, agreements and conditions hereafter set forth, and intending to be legally bound hereby, the parties hereeto agree as follows:

ARTICLE I

SETTLEMENT OF UARS AND EARS; SALE OF UNITS; CLOSING

SECTION 1.1 Settlement of UARs and EARS; Purchase and Sale of Units;

or arrangement nor, to the Knowledge of the Company, has any termination of any such policies or arrangements been threatened.

SECTION 2.17 Intellectual Property. Except as set forth in Section 2.17 of the Company Disclosure Schedule:

(a) The Company and its Subsidiaries own free and clear of all Encumbrances or have the right to use pursuant to a License Agreement all patents, new drug application, drug master file, trademarks and service marks, domain names, copyrights, computer software, trade secrets, and other intellectual property, necessary or used for the operation of the business of the Company and its Subsidiaries as currently conducted, collectively, the "Company Intellectual Property". The Company Intellectual Property is valid, subsisting and enforceable, and the Company has taken reasonable measures to maintain and protect the Company Intellectual Property.

(b) Section 2.17(b) of the Company Disclosure Schedule sets forth, for the intellectual property owned or used by the Company and its Subsidiaries, a complete list of all: (i) patents and patent applications; (ii) trademark registrations and trademark applications; (iii) Internet domain name registrations; (iv) copyright registrations and copyright applications, (v) trade or corporate names, (vi) material unregistered trademarks, and (vii) material computer software (other than commercially available, shrink-wrap software with a replacement cost and/or annual license fee of less than \$25,000). Section 2.17(b) of the Company Disclosure Schedule also sets forth a complete and accurate list of all licenses and other agreements under which the Company or any of its Subsidiaries grants or obtains any rights in or to any intellectual property (other than licenses for commercially available, shrink-wrap software with a replacement cost and/or annual license fee of less than \$25,000) (collectively, "License Agreements"). There are no pending or, to the Knowledge of the Company, threatened proceedings or litigation or other adverse claims by any Person against the Company or any of its Subsidiaries contesting the use or ownership by the Company and its Subsidiaries or the validity or enforceability of any Company Intellectual Property, and no such claims were made against the Company or any of its Subsidiaries within the past five (5) years. The Company Intellectual Property is not subject to any outstanding consent, settlement, decree, order, injunction, judgment or ruling restricting the use thereof.

(c) To the Knowledge of the Company, (i) the conduct of the business of the Company and its Subsidiaries as currently conducted does not infringe upon, misappropriate or otherwise conflict with the intellectual property rights of any third party, and the Company and its Subsidiaries have not received any notice of the foregoing (including any offers or demands to license any intellectual property), and (ii) to the Knowledge of the Company no third party is infringing upon, misappropriating or otherwise conflicting with any Company Intellectual Property.

SECTION 2.18 Food and Drug Administration.

Company Disclosure Schedule

Section 2.17(b)

Intellectual Property

U.S. Patent No. 5,842,474 (FEI Products, Inc. n/k/a FEI Products LLC)
U.S. Trademark Application Serial Nos. 76/474,556 and 76/198,553 (FEI
Acquisition LLC, n/k/a FWH)

ParaGard Trademark – US

ParaGard Trademark – Canada

Liber-T Trademark Application

Liber-T Design Application

“Birth control that fits your life” – Trademark Application

FEI

FEI

feiproducts.com

fei-womenshealth.com

liber-t.biz

liber-t.info

liber-t.tv

liber-t.us

liber-tiud.com

liber-tiud.info

liber-tiud.net

liber-tiud.org

liber-tiud.us

liber-tiud.tv

myiud.com

paragard.net

paragard.org

paraguard.com

ParaGard.com

ParaGardIUC.com

Paragardsales.com

theiud.com

paragardus.com

Telesis – Manufacturing and General Ledger Package

Microsoft Office Professional

Seibel Licenses

Report Toolkit (customer software)

Paragardsales.com (custom web application)

IN WITNESS WHEREOF, the parties hereto have caused this Agreement
duly executed by their respective authorized officers as of the date and year first
written.


COPPER 380T, LLC

By: _____
Name:
Title:

FEI WOMEN'S HEALTH, L.L.C.

By: _____
Name:
Title:

DURAMED PHARMACEUTICALS, INC.

By: 
Name: Paul M. Bismo
Title: President

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed by their respective authorized officers as of the date and year first above written.

COPPER 380T, LLC

By: Y. S. M., CO-CHAIRMAN
Name:
Title:

FEI WOMEN'S HEALTH. L.L.C.

By: Y. S. M., CO-CHAIRMAN
Name:
Title:

DURAMED PHARMACEUTICALS, INC.

By: _____
Name:
Title: